45 related articles for article (PubMed ID: 38454451)
21. Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma.
Nuersulitan R; Yang M; Mi L; Wu M; Liu X; Ping L; Xie Y; Liu W; Song Y; Zhu J
Cancer Manag Res; 2021; 13():6731-6741. PubMed ID: 34471386
[TBL] [Abstract][Full Text] [Related]
22. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH; Moskowitz AJ; Bartlett NL; Vose JM; Ramchandren R; Feldman TA; LaCasce AS; Christian BA; Ansell SM; Moskowitz CH; Brown L; Zhang C; Taft D; Ansari S; Sacchi M; Ho L; Herrera AF
Blood; 2021 Aug; 138(6):427-438. PubMed ID: 33827139
[TBL] [Abstract][Full Text] [Related]
24. Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation.
Bai B; Wang XX; Gao Y; Li PF; He HX; Ping LQ; Huang C; Cai QC; Huang HQ
Bone Marrow Transplant; 2021 May; 56(5):1151-1158. PubMed ID: 33273659
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
26. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
Manson G; Brice P; Herbaux C; Silva MG; Bouabdallah K; Deau B; Bouteloup J; Schiano JM; Nicolas-Virelizier E; Maerevoet M; Ghesquieres H; Stamatoullas A; Antier C; Carlo-Stella C; de Charette M; Poizeau F; Dercle L; Houot R
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1144-1153. PubMed ID: 32860075
[TBL] [Abstract][Full Text] [Related]
27. Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.
Poonsombudlert K; Kewcharoen J; Prueksapraopong C; Limpruttidham N
Hawaii J Health Soc Welf; 2020 Jun; 79(6):194-201. PubMed ID: 32524098
[TBL] [Abstract][Full Text] [Related]
28. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R; Sureda A; de la Cruz F; Canales M; Gonzalez AP; Pinana JL; Rodriguez A; Gutierrez A; Domingo-Domenech E; Sanchez-Gonzalez B; Rodriguez G; Lopez J; Moreno M; Rodriguez-Salazar MJ; Jimenez-Cabrera S; Caballero MD; Martinez C
Ann Oncol; 2019 Apr; 30(4):612-620. PubMed ID: 30657848
[TBL] [Abstract][Full Text] [Related]
31. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy.
Wu X; Li Y; Liu X; Chen C; Harrington SM; Cao S; Xie T; Pham T; Mansfield AS; Yan Y; Kwon ED; Wang L; Ling K; Dong H
Heliyon; 2018 Dec; 4(12):e01039. PubMed ID: 30603685
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi C; Gilhodes J; Maerevoet M; Herbaux C; Morschhauser F; Brice P; Garciaz S; Borel C; Ysebaert L; Obéric L; Lazarovici J; Deau B; Dupuis J; Chauchet A; Abraham J; Bijou F; Stamatoullas-Bastard A; Malfuson JV; Golfier C; Laurent C; Pericart S; Traverse-Glehen A; Kanoun S; Filleron T; Casasnovas RO; Ghesquières H
Am J Hematol; 2018 Jun; ():. PubMed ID: 29884994
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
36. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.
Gutierrez A; Rodriguez J; Martinez-Serra J; Gines J; Paredes P; Garcia F; Vercher J; Balanzat J; Del Campo R; Galan P; Morey M; Sampol A; Novo A; Bento L; García L; Bargay J; Besalduch J
Onco Targets Ther; 2014; 7():2093-100. PubMed ID: 25419147
[TBL] [Abstract][Full Text] [Related]
38. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
39. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
Lesterhuis WJ; Punt CJ; Hato SV; Eleveld-Trancikova D; Jansen BJ; Nierkens S; Schreibelt G; de Boer A; Van Herpen CM; Kaanders JH; van Krieken JH; Adema GJ; Figdor CG; de Vries IJ
J Clin Invest; 2011 Aug; 121(8):3100-8. PubMed ID: 21765211
[TBL] [Abstract][Full Text] [Related]
40. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Yahalom J; Kewalramani T; Maragulia JC; Vanak JM; Zelenetz AD; Moskowitz CH
Blood; 2010 Dec; 116(23):4934-7. PubMed ID: 20733154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]